Component

Rat absolute oral bioavailability of RA

Rat absolute oral bioavailability of RA

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.

    Experimental context and source evidence
    evidence_access
    Publisher-indexed primary Methods, Results and Table 2 read through web retrieval; local HTML download blocked.
    experimental_model
    Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.
    primary_references
    Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality | https://pubs.rsc.org/en/content/articlehtml/2017/ra/c6ra28237g
    source_locator
    Reviewed reference ra-rat-bioavailability; Table 2; dose-normalized oral versus IV AUC. These values are not established human bioavailability.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 27–33

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS. · Recorded from source · Recorded from source

    ### ra-rat-bioavailability Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively. Table 2; dose-normalized oral versus IV AUC. These values are not established human bioavailability. Model and exposure: Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality | 2017 | https://pubs.rsc.org/en/content/articlehtml/2017/ra/c6ra28237g | Access: Publisher-indexed primary Methods, Results and Table 2 read through web retrieval; local HTML download blocked.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.